news
-
8 September 2021Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma
Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announces that United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has accepted a Market Authorisation Application (MAA) seeking the approval of tebentafusp (IMCgp100) for the treatment of patients with metastatic uveal melanoma (mUM).
Tebentafusp is also being reviewed in the UK under the U.S. Food and Drug Administration’s (FDA) Project Orbis initiative, which enables concurrent review by the health authorities in participating partner countries. As previously announced, the FDA and European Medicines Agency have accepted the Biologics License Application (BLA) and MAA respectively for tebentafusp. In the United States, the BLA was initiated and will be reviewed under the Real-Time Oncology Review (RTOR) pilot program.
The regulatory submissions for tebentafusp are based on data from the randomized Phase 3 IMCgp100-202 clinical trial evaluating tebentafusp in previously untreated metastatic uveal melanoma, a cancer that has historically proven to be frequently insensitive to other immunotherapies. In the final study analysis, tebentafusp demonstrated clinically and statistically significant superior overall survival (OS) benefit as a monotherapy. The primary endpoint was achieved with the OS Hazard Ratio (HR) in the intent-to-treat population favoring tebentafusp, HR=0.51 [95% CI (0.37, 0.71); p< 0.0001] over investigator’s choice (82% pembrolizumab; 12% ipilimumab; 6% dacarbazine).
Bahija Jallal, Chief Executive Officer of Immunocore, said: “We are delighted that the MHRA has accepted our application for tebentafusp and the FDA has selected tebentafusp for the Project Orbis initiative. As a UK-founded biotech company pioneering the field of TCR therapeutics, we are encouraged with these regulatory milestones that brings us closer to helping people with metastatic uveal melanoma in the UK and abroad. The regulatory agencies recognise the urgent need for an approved treatment specific to mUM, an aggressive form of cancer for which the recommended option for patients is enrolment into a clinical trial.”
Related
Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update
Immunocore Reports First Quarter 2021 Financial Results
Immunocore Provides Business Update and Reports Full Year 2020 Financial Results
Immunocore Announces Closing of $312.1 Million Financing
Immunocore Announces Pricing of Upsized Initial Public Offering
Immunocore announces closing of $75.0 Million Series C round
Immunocore announces dosing of first patient with fourth ImmTAC
First Site in Global Uveal Melanoma Patient Registry Now Open
Immunocore announces dosing of first patient with third ImmTAC® bispecific
Detailed Review of Tebentafusp (IMCgp100) in Metastatic Uveal Melanoma Published in Issue of Cancers
Immunocore’s Lead Asset Tebentafusp Gains Fast Track Designation for Metastatic Uveal Melanoma
Immunocore appoints Bahija Jallal as Chief Executive Officer
Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech
Immunocore strengthens IP position in the field of TCR-based therapeutics
Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours
Immunocore Announces Management Change
Immunocore wins Large Business of the Year at the 2018 Vale4Business Awards
Immunocore Announces Leadership Change
Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer
Immunocore and MEPC announce significant laboratory expansion at Milton Park in Oxfordshire, UK
Immunocore Announces Third Oncology Target Selected in Discovery Collaboration with GlaxoSmithKline
Immunocore identifies second novel ImmTAC® in the GSK collaboration
Immunocore wins Financing Deal of the Year at the 12th Annual SCRIP Awards 2016
Immunocore Appoints Paul Fry as Chief Financial Officer
Immunocore Ranked in the Sunday Times Hiscox Tech Track 100
Immunocore Wins Private UK Life Science Company of the Year at Biotech and Money Assembly and Awards
Immunocore’s IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma
Immunocore’s IMCgp100 Granted Orphan Drug Designation by US FDA for the Treatment of Uveal Melanoma
Immunocore Starts Clinical Trial with IMCgp100 in Combination with MedImmune Immunotherapies Durvalumab and Tremelimumab
Immunocore and GlaxoSmithKline Select First ImmTAC Clinical Candidate in Discovery Collaboration
Immunocore expands its senior management team and opens US Office
Immunocore wins Biotech of the Year at the SCRIP Awards 2015